Pfeiffer Philipp, Buchholz Vanessa, Probst Chris, Ghazy Ahmed, Rissel René, Griesinger Jan, Treede Hendrik, Dohle Daniel-Sebastian
Department of Cardiovascular Surgery, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Department of Cardiovascular Surgery, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany.
Arch Cardiovasc Dis. 2025 Jun-Jul;118(6-7):365-373. doi: 10.1016/j.acvd.2025.02.004. Epub 2025 Mar 18.
In acute type A dissection, the coagulation system is impaired by the dissection and its complications as well as the use of the heart-lung machine with hypothermia. Because of the critical importance of effective haemostasis at the end of the operation, the use of coagulation products and blood transfusions is usually unavoidable.
This retrospective study aims to analyse the use of blood products and coagulation factors in the context of acute aortic dissections, and the factors influencing their use.
Between 2017 and 2022, 369 patients were operated on for acute type A dissection. Clinical details, including the status at presentation and perioperatively administered transfusions and coagulation factors were obtained, and patients were stratified according to the Penn classification. A multivariable linear regression analysis for transfusions and coagulation factors was conducted, including typical risk factors.
The use of perioperatively required transfusions and coagulation factor (prothrombin complex concentrate and fibrinogen) substitution increased significantly with a higher ischaemic burden, including both localized and generalized malperfusion (Penn A<B<C<BC; P≤0.017). Multivariable linear regression analysis revealed that, besides generalized ischaemia, duration of cardiopulmonary bypass, extent of surgery and patient size were other significant factors.
Surgical repair for acute type A dissection remains major surgery, requiring transfusions and coagulation factors in almost all patients. The ischaemic burden was identified as the most important factor that necessitates the use of these products, and was associated with early death. With proper management, acceptable rethoracotomy and chest drain rates with good clinical outcomes can be achieved.
在急性A型主动脉夹层中,凝血系统会因夹层及其并发症以及体外循环联合低温的使用而受损。由于手术结束时有效止血至关重要,因此通常不可避免地要使用凝血产品和输血。
这项回顾性研究旨在分析急性主动脉夹层患者血液制品和凝血因子的使用情况及其影响因素。
2017年至2022年期间,369例患者接受了急性A型主动脉夹层手术。获取了临床详细信息,包括就诊时的状况以及围手术期输血和凝血因子的使用情况,并根据宾夕法尼亚分类法对患者进行分层。对输血和凝血因子进行了多变量线性回归分析,纳入了典型风险因素。
围手术期所需输血和凝血因子(凝血酶原复合物浓缩物和纤维蛋白原)替代物的使用随着缺血负担的增加而显著增加,包括局部和全身性灌注不良(宾夕法尼亚分类法A<B<C<BC;P≤0.017)。多变量线性回归分析显示,除全身性缺血外,体外循环时间、手术范围和患者体型也是其他重要因素。
急性A型主动脉夹层的手术修复仍然是大手术,几乎所有患者都需要输血和凝血因子。缺血负担被确定为需要使用这些产品的最重要因素,并且与早期死亡相关。通过适当管理,可以实现可接受的再次开胸手术率和胸腔引流率,并取得良好的临床结果。